Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kideny disorder therapeutics - Visterra

Drug Profile

Research programme: kideny disorder therapeutics - Visterra

Latest Information Update: 07 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Visterra
  • Class Anti-inflammatories; Antibodies; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anti-neutrophil cytoplasmic antibody-associated vasculitis; Graft-versus-host disease; Lupus nephritis; Membranous glomerulonephritis; Renal transplant rejection

Most Recent Events

  • 26 Aug 2021 Kideny disorder therapeutics - Visterra is available for licensing as of 26 Aug 2021. https://www.visterrainc.com/#contactus
  • 20 Aug 2021 Preclinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis in USA (Parenteral) before August 2021 (Visterra pipeline, August 2021)
  • 20 Aug 2021 Preclinical trials in Graft-versus-host disease in USA (Parenteral) before August 2021 (Visterra pipeline, August 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top